Appili Therapeutics Inc (APLI) - Net Assets
Based on the latest financial reports, Appili Therapeutics Inc (APLI) has net assets worth CA$-16.38 Million CAD (≈ $-11.85 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$547.91K ≈ $396.35K USD) and total liabilities (CA$16.93 Million ≈ $12.25 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Appili Therapeutics Inc (APLI) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-16.38 Million |
| % of Total Assets | -2990.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | -205.05% |
| 10-Year Change | N/A |
| Growth Volatility | 125.31 |
Appili Therapeutics Inc - Net Assets Trend (2017–2025)
This chart illustrates how Appili Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore APLI total asset value for the complete picture of this company's asset base.
Annual Net Assets for Appili Therapeutics Inc (2017–2025)
The table below shows the annual net assets of Appili Therapeutics Inc from 2017 to 2025. For live valuation and market cap data, see Appili Therapeutics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | CA$-13.40 Million ≈ $-9.69 Million |
-22.63% |
| 2024-03-31 | CA$-10.92 Million ≈ $-7.90 Million |
-47.69% |
| 2023-03-31 | CA$-7.40 Million ≈ $-5.35 Million |
-126.17% |
| 2022-03-31 | CA$-3.27 Million ≈ $-2.37 Million |
-125.65% |
| 2021-03-31 | CA$12.75 Million ≈ $9.23 Million |
+44.17% |
| 2020-03-31 | CA$8.85 Million ≈ $6.40 Million |
+100.14% |
| 2019-03-31 | CA$4.42 Million ≈ $3.20 Million |
-9.19% |
| 2018-03-31 | CA$4.87 Million ≈ $3.52 Million |
+254.07% |
| 2017-03-31 | CA$1.37 Million ≈ $994.41K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Appili Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6881562200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$42.32 Million | % |
| Other Comprehensive Income | CA$1.18 Million | % |
| Other Components | CA$14.82 Million | % |
| Total Equity | CA$-13.40 Million | 100.00% |
Appili Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Appili Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
NASDAQ:CUPR
|
$1.86 Million |
|
Mobeus Income And Growth Vct Plc
LSE:MIX
|
$1.86 Million |
|
OurLiving AB
ST:OURLIV
|
$1.86 Million |
|
Camellia Plc
LSE:CAM
|
$1.87 Million |
|
Helios Underwriting PLC
LSE:HUW
|
$1.85 Million |
|
Alpha Star Acquisition Corp
NASDAQ:ALSA
|
$1.85 Million |
|
Gentlemens Equity S.A.
PA:MLGEQ
|
$1.85 Million |
|
Fintech Chain Ltd
AU:FTC
|
$1.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Appili Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -10,924,779 to -13,397,340, a change of -2,472,561.
- Net loss of 2,624,692 reduced equity.
- Other comprehensive income decreased equity by 1,795,965.
- Other factors increased equity by 1,948,096.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-2.62 Million | -19.59% |
| Other Comprehensive Income | CA$-1.80 Million | -13.41% |
| Other Changes | CA$1.95 Million | +14.54% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Appili Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | CA$0.05 | CA$0.02 | x |
| 2018-03-31 | CA$0.15 | CA$0.02 | x |
| 2019-03-31 | CA$0.15 | CA$0.02 | x |
| 2020-03-31 | CA$0.26 | CA$0.02 | x |
| 2021-03-31 | CA$0.22 | CA$0.02 | x |
| 2022-03-31 | CA$-0.05 | CA$0.02 | x |
| 2023-03-31 | CA$-0.07 | CA$0.02 | x |
| 2024-03-31 | CA$-0.09 | CA$0.02 | x |
| 2025-03-31 | CA$-0.11 | CA$0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Appili Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2613.12%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-53.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -127.61% | 0.00% | 0.00x | 1.87x | CA$-1.89 Million |
| 2018 | -81.69% | 0.00% | 0.00x | 1.48x | CA$-4.46 Million |
| 2019 | -97.99% | 0.00% | 0.00x | 1.55x | CA$-4.77 Million |
| 2020 | -61.23% | -2720.41% | 0.02x | 1.26x | CA$-6.30 Million |
| 2021 | -112.33% | -7194.72% | 0.01x | 1.44x | CA$-15.60 Million |
| 2022 | 0.00% | -1806.18% | 0.17x | 0.00x | CA$-24.79 Million |
| 2023 | 0.00% | -2765.90% | 0.11x | 0.00x | CA$-8.50 Million |
| 2024 | 0.00% | -456.96% | 0.56x | 0.00x | CA$-2.69 Million |
| 2025 | 0.00% | -2613.12% | 0.03x | 0.00x | CA$-1.28 Million |
Industry Comparison
This section compares Appili Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $28,388,077
- Average return on equity (ROE) among peers: -421.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Appili Therapeutics Inc (APLI) | CA$-16.38 Million | -127.61% | N/A | $1.86 Million |
| Aptose Biosciences Inc (APS) | $7.33 Million | -189.11% | 0.18x | $4.36 Million |
| Arch Biopartners Inc (ARCH) | $1.06 Million | -79.15% | 0.19x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-1.30 Million | 0.00% | 0.00x | $6.98 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $1.18 Million | -3177.89% | 21.71x | $393.86 Million |
| Devonian Health Group Inc (GSD) | $14.25 Million | -32.28% | 0.35x | $20.01 Million |
| Helix BioPharma Corp. (HBP) | $-1.39 Million | 0.00% | 0.00x | $116.58 Million |
| Hemostemix Inc (HEM) | $-6.77 Million | 0.00% | 0.00x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $3.94 Million | -266.20% | 0.60x | $1.13 Million |
About Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more